AME Q1 2026 Earnings Call Summary

Sales: $1.93 billion, up 11% year-over-year; organic sales increased by 5%.
Orders: Record orders of $2.2 billion, up 23% year-over-year; organic orders rose 22%.
Operating Income: $517 million, a 14% increase; operating margins at 26.8%.
Core Margins: 27.9%, up 160 basis points from Q1 2025.
EBITDA: Record $620 million, up 11% with EBITDA margins at 32.1%.
Free Cash Flow: $426 million, up 8% year-over-year; conversion rate of 107%.
Diluted EPS: $1.97, up 13% and above guidance of $1.85 to $1.90.

AMETEK announced the acquisition of First Aviation Services, enhancing its defense aftermarket capabilities.
Strong performance in the Electronic Instruments Group (EIG) with double-digit sales growth and significant order increases, particularly in defense and semiconductor sectors.
Electromechanical Group (EMG) also showed robust results, with sales up 13% and core operating margins up 410 basis points.
Notable orders included contracts in defense, aerospace, and semiconductor markets, reflecting AMETEK's strong positioning in niche markets.

Full-year sales expected to increase high single digits; organic sales projected to grow mid-single digits.
Diluted EPS guidance raised to $7.94 to $8.14, reflecting a 7% to 10% increase year-over-year.
For Q2 2026, sales are anticipated to rise high single digits with adjusted EPS of $1.96 to $2.00, up 10% to 12% from the prior year.

Geopolitical Risks: Ongoing uncertainty, particularly in the Middle East, although AMETEK's exposure is minimal (2% of sales).
Potential Market Headwinds: Concerns about macroeconomic pressures and inflation, though management remains optimistic about order strength.
Aerospace Aftermarket: Some emerging concerns about the commercial aerospace aftermarket potentially peaking, particularly in Europe and Asia, which could impact future growth.

Management reported balanced growth across geographies, with Asia showing the strongest performance.
No significant cancellations or delays were noted in orders, and the company remains confident in its order pipeline.
Discussions around larger M&A opportunities were addressed, emphasizing a disciplined approach to acquisitions while maintaining a strong financial position.
The medical segment showed low double-digit growth, primarily driven by strong performance from the Paragon business, though tougher comps are expected later in the year.
Management is closely monitoring input costs and inflation, with strategies in place to mitigate these risks through pricing adjustments.

Overall, AMETEK's Q1 2026 results reflect strong operational performance and a positive outlook, despite some external challenges and uncertainties.

AME — AMETEK, Inc.